Cardiff Oncology Inc (NASDAQ: CRDF) kicked off on Friday, up 19.88% from the previous trading day, before settling in for the closing price of $3.27. Over the past 52 weeks, CRDF has traded in a range of $1.25-$6.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 9.26%. While this was happening, its average annual earnings per share was recorded -7.07%. With a float of $47.52 million, this company’s outstanding shares have now reached $48.73 million.
Let’s determine the extent of company efficiency that accounts for 32 employees. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 7.06%, while institutional ownership is 24.93%. The most recent insider transaction that took place on Dec 11 ’24, was worth 910,299. In this transaction Director of this company bought 350,115 shares at a rate of $2.60, taking the stock ownership to the 1,047,876 shares. Before that another transaction happened on Dec 11 ’24, when Company’s Director bought 11,500 for $2.60, making the entire transaction worth $29,900. This insider now owns 1,059,376 shares in total.
Cardiff Oncology Inc (CRDF) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -7.07% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Take a look at Cardiff Oncology Inc’s (CRDF) current performance indicators. Last quarter, stock had a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 453.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Looking closely at Cardiff Oncology Inc (NASDAQ: CRDF), its last 5-days average volume was 12.91 million, which is a jump from its year-to-date volume of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 70.62%. Additionally, its Average True Range was 0.41.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 80.59%, which indicates a significant decrease from 85.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 205.22% in the past 14 days, which was higher than the 114.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.89, while its 200-day Moving Average is $3.18. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $4.18. Second resistance stands at $4.45. The third major resistance level sits at $4.81. If the price goes on to break the first support level at $3.55, it is likely to go to the next support level at $3.19. Now, if the price goes above the second support level, the third support stands at $2.92.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
The company with the Market Capitalisation of 312.61 million has total of 51,134K Shares Outstanding. Its annual sales at the moment are 490 K in contrast with the sum of -41,440 K annual income. Company’s last quarter sales were recorded 170 K and last quarter income was -11,860 K.
